So far, Gilead Sciences' Kite Pharma has been buying from contractors the viral vector material needed for its chimeric antigen receptor T-cell (CAR-T) treatment Yescarta. But with an expanding pipeline of cell therapies, the company says it is time to be able to produce its own.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,